Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Impact of conditioning intensity of allo-SCT for AML with molecular residual disease

Christopher Hourigan • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia
BMT CTN 0901

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses his group’s work on the impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia (AML) with genomic evidence of residual disease. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Christopher Hourigan

1:39
How can MRD guide treatment of AML?
Christopher Hourigan • 4 Jun 2022
1:11
Current role of MRD in AML
Christopher Hourigan • 4 Jun 2022
1:09
Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Christopher Hourigan • 4 Jun 2022
2:50
Conditioning intensity and genomics: relapse after allogeneic transplant in MDS
Christopher Hourigan • 16 Jun 2020

Related Videos

1:49
Exciting therapeutic approaches in the AML space
Steven Knapper • 1 May 2024
4:16
The novel bioactive peptide QUB-2392 shows anti-leukemic effects in leukemia cell lines
Ruth Gyereh • 28 Apr 2024
3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals